Brain magnetic stimulation to reduce levodopa-induced dyskinesias in Parkinson's disease

脑磁刺激可减少帕金森病中左旋多巴引起的运动障碍

• 批准号: 488794
• 负责人: Di Paolo-Chenevert Thrèse
• 金额: $ 20.06万
• 依托单位: Universit Laval
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-09-01 至 2025-09-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=488794&lang=en
• 关键词: Amantadine; Brain Magnetic Stimulation; Dopamine; Dyskinesias; Glutamate Receptors; Levodopa; Monkey; Motor Behaviour Measures; Mptp; Parkinson'S Disease

The chronic exposure of people with Parkinson's disease (PD) to levodopa, the gold standard medication, mostly leads to the development of abnormal involuntary movements called dyskinesias that reduce the quality of life and are difficult to treat. Dyskin

帕金森病（PD）患者长期暴露于左旋多巴（金标准药物），主要导致称为运动障碍的异常不自主运动的发展，降低生活质量，难以治疗。